MRK · News · 20260901N

Melanoma Vaccine Collaboration

Merck & Co., Inc. · 2026-09-01 · Importance 31 · Surprise 42

Merck and Moderna reported positive Phase 3 results for a personalized mRNA cancer vaccine targeting melanoma on September 1, 2026. The collaboration combines Moderna’s mRNA technology with Merck’s oncology expertise and is focused on personalized immunotherapy for solid tumors. The results increased investor attention to cancer vaccines and precision-medicine opportunities, although the reports did not disclose revenue, development costs, regulatory filings, or commercialization economics.

Key facts

• Merck and Moderna have achieved positive results in a Phase 3 trial for their mRNA cancer vaccine for melanoma. source
• Merck & Co Inc's (NYSE:MRK) positive Phase 3 results were for a personalized mRNA cancer vaccine. source